MA50675A - Inhibiteurs de la creb binding protein (cbp) - Google Patents

Inhibiteurs de la creb binding protein (cbp)

Info

Publication number
MA50675A
MA50675A MA050675A MA50675A MA50675A MA 50675 A MA50675 A MA 50675A MA 050675 A MA050675 A MA 050675A MA 50675 A MA50675 A MA 50675A MA 50675 A MA50675 A MA 50675A
Authority
MA
Morocco
Prior art keywords
cbp
inhibitors
binding protein
creb binding
creb
Prior art date
Application number
MA050675A
Other languages
English (en)
Other versions
MA50675B1 (fr
Inventor
Jennifer R Downing
Anna Ericsson
Bradford Graves
Torsten Herbertz
Hongbin Li
Steven Mischke
Shawn E R Schiller
Angela V West
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051235 external-priority patent/WO2019055877A1/fr
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA50675A publication Critical patent/MA50675A/fr
Publication of MA50675B1 publication Critical patent/MA50675B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA50675A 2018-06-29 2019-07-01 Inhibiteurs de la creb binding protein (cbp) MA50675B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
PCT/US2018/051235 WO2019055877A1 (fr) 2017-09-15 2018-09-14 Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
PCT/US2018/051214 WO2019055869A1 (fr) 2017-09-15 2018-09-14 Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
US201962819490P 2019-03-15 2019-03-15
US16/457,596 US10870648B2 (en) 2018-06-29 2019-06-28 Inhibiting CREB binding protein (CBP)
PCT/US2019/039936 WO2020006483A1 (fr) 2018-06-29 2019-06-28 Inhibition de la protéine de liaison à creb (cbp)

Publications (2)

Publication Number Publication Date
MA50675A true MA50675A (fr) 2021-04-07
MA50675B1 MA50675B1 (fr) 2021-09-30

Family

ID=68987627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50675A MA50675B1 (fr) 2018-06-29 2019-07-01 Inhibiteurs de la creb binding protein (cbp)

Country Status (26)

Country Link
US (3) US10870648B2 (fr)
EP (1) EP3998266A1 (fr)
JP (4) JP6781806B2 (fr)
KR (2) KR102805503B1 (fr)
CN (2) CN116178369A (fr)
AU (3) AU2019295790B2 (fr)
BR (1) BR112020026783A2 (fr)
CA (1) CA3105099A1 (fr)
CY (1) CY1124762T1 (fr)
DK (1) DK3587418T3 (fr)
ES (1) ES2900105T3 (fr)
HR (1) HRP20211698T1 (fr)
HU (1) HUE056885T2 (fr)
IL (3) IL279734B2 (fr)
LT (1) LT3587418T (fr)
MA (1) MA50675B1 (fr)
MX (2) MX2023013508A (fr)
PL (1) PL3587418T3 (fr)
PT (1) PT3587418T (fr)
RS (1) RS62732B1 (fr)
SA (1) SA520420909B1 (fr)
SG (1) SG11202012767UA (fr)
SI (1) SI3587418T1 (fr)
SM (1) SMT202100636T1 (fr)
WO (1) WO2020006483A1 (fr)
ZA (2) ZA202100509B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10870648B2 (en) * 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)
EP3938365A4 (fr) * 2019-03-15 2023-01-25 Forma Therapeutics, Inc. Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer
WO2020190791A1 (fr) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibition de la protéine de liaison à un élément sensible à l'amp cyclique (creb)
KR20230028798A (ko) 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
BR112022025911A2 (pt) 2020-06-25 2023-01-10 Tolremo Therapeutics Ag Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
KR100865775B1 (ko) 2000-11-20 2008-10-29 메르크 파텐트 게엠베하 키랄 광이성질성 화합물
WO2003033517A1 (fr) 2001-10-17 2003-04-24 The University Of British Columbia Modulateurs de ship 1
EP1460067A4 (fr) 2001-11-26 2005-12-07 Takeda Pharmaceutical Derive bicyclique, procede de production de ce derive et utilisation correspondante
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (fr) 2003-11-13 2008-10-06
WO2005066162A1 (fr) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Composes synthetiques et derives de ceux-ci en tant que modulateurs de fumee ou d'ingestion de nicotine et du cancer du poumon
EP1732541A4 (fr) 2004-04-07 2008-03-05 Takeda Pharmaceutical Composes cycliques
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
US20080318989A1 (en) 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
EP1878724A1 (fr) 2006-07-15 2008-01-16 sanofi-aventis Synthèse régiosélective des benzimidazoles et azabenzimidazoles catalysée par le palladium
CA2574531C (fr) 2007-01-19 2016-10-25 The University Of British Columbia Promoteurs de l'acetylation d'hat et utilisations de compositions contenant ceux-ci pour promouvoir l'immunogenicite
US8476458B2 (en) 2007-06-21 2013-07-02 The Wistar Institute Methods and compositions for modulating P300/CBP activity
WO2009000413A1 (fr) 2007-06-26 2008-12-31 Sanofi-Aventis Synthèse régiosélective catalysée par le cuivre de benzimidazoles et d'azabenzimidazoles
US8222417B2 (en) 2007-06-27 2012-07-17 Taisho Pharmaceutical Co., Ltd Compound having 11β-HSD1 inhibitory activity
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
MX2010014066A (es) 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
WO2010110380A1 (fr) * 2009-03-27 2010-09-30 興和株式会社 Composé de pipéridine condensé et agent pharmaceutique le contenant
WO2010118208A1 (fr) 2009-04-09 2010-10-14 Exelixis, Inc. Dérivés benzoxazepin-4-(5h)-yle et leur utilisation pour traiter le cancer
CA2758904C (fr) 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Nouveaux composes du type mimetique a spire inversee, procede pour leur preparation et utilisation
WO2010138490A1 (fr) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazèpines comme inhibiteurs de mtor et méthodes d'utilisation et de fabrication
CN102459248A (zh) 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
WO2012080729A2 (fr) 2010-12-14 2012-06-21 Electrophoretics Limited Inhibiteurs de caséine kinase 1δ (ck1δ)
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
EP2678050B1 (fr) 2011-02-24 2020-10-14 Emory University Compositions antagonistes de noggine pour ossification et procédés associés à celles-ci
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (fr) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. Inhibiteurs de p300/cbp et leurs méthodes d'utilisation
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
TW201605859A (zh) 2013-11-14 2016-02-16 必治妥美雅史谷比公司 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
EP3193866A1 (fr) 2014-09-19 2017-07-26 Genentech, Inc. Utilisation des inhibiteurs cbp/ep300 et bet pour le traitement du cancer
EP3632915A1 (fr) * 2014-11-27 2020-04-08 Genentech, Inc. Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300
WO2016110821A1 (fr) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales de ceux-ci
WO2016128908A1 (fr) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales correspondantes
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
EP3464270B1 (fr) 2016-05-24 2022-02-23 Genentech, Inc. Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018195155A1 (fr) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Composés thérapeutiques
TWI795440B (zh) * 2017-09-15 2023-03-11 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
US10870648B2 (en) * 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)

Also Published As

Publication number Publication date
MA50675B1 (fr) 2021-09-30
AU2019295790B2 (en) 2023-07-13
BR112020026783A2 (pt) 2021-03-30
US12378242B2 (en) 2025-08-05
AU2019295790A1 (en) 2021-01-28
KR20250067962A (ko) 2025-05-15
US20200002332A1 (en) 2020-01-02
AU2023226653A1 (en) 2023-09-21
IL313466B2 (en) 2025-11-01
KR20210025631A (ko) 2021-03-09
IL313466A (en) 2024-08-01
HRP20211698T1 (hr) 2022-02-18
CY1124762T1 (el) 2022-07-22
ZA202100509B (en) 2022-12-21
HUE056885T2 (hu) 2022-03-28
JP6781806B2 (ja) 2020-11-04
JP2020128426A (ja) 2020-08-27
MX2023013508A (es) 2023-12-13
LT3587418T (lt) 2021-11-25
SA520420909B1 (ar) 2024-11-12
US20220162207A1 (en) 2022-05-26
CN112513038B (zh) 2023-01-10
WO2020006483A1 (fr) 2020-01-02
JP7017801B2 (ja) 2022-02-09
RS62732B1 (sr) 2022-01-31
SMT202100636T1 (it) 2022-01-10
DK3587418T3 (da) 2021-10-11
JP2025094157A (ja) 2025-06-24
CA3105099A1 (fr) 2020-01-02
KR102805503B1 (ko) 2025-05-09
US10870648B2 (en) 2020-12-22
AU2025210762A1 (en) 2025-08-21
JP2020002135A (ja) 2020-01-09
ES2900105T3 (es) 2022-03-15
PT3587418T (pt) 2021-12-02
US11254674B2 (en) 2022-02-22
PL3587418T3 (pl) 2022-02-21
SI3587418T1 (sl) 2022-03-31
JP2021042255A (ja) 2021-03-18
CN112513038A (zh) 2021-03-16
IL321337A (en) 2025-08-01
MX2020014303A (es) 2021-03-25
SG11202012767UA (en) 2021-01-28
CN116178369A (zh) 2023-05-30
EP3998266A1 (fr) 2022-05-18
ZA202210560B (en) 2025-12-17
IL279734B2 (en) 2024-11-01
IL313466B1 (en) 2025-07-01
US20200299295A1 (en) 2020-09-24
IL279734B1 (en) 2024-07-01
AU2023226653B2 (en) 2025-09-04
IL279734A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
IL282179A (en) Protein tyrosine phosphatase inhibitors
IL286462A (en) Protein tyrosine phosphatase inhibitors
IL281962A (en) Il-12 heterodimeric fc-fusion proteins
EP3932338C0 (fr) Tourniquet
EP3630783A4 (fr) Inhibiteurs protéiques de liaison à la pénicilline
MA50675A (fr) Inhibiteurs de la creb binding protein (cbp)
EP3621994A4 (fr) Protéines de liaison à la mésothéline
MA54543A (fr) Inhibiteurs de kif18a
EP3630782A4 (fr) Inhibiteurs de protéines de liaison à la pénicilline
MA54550A (fr) Inhibiteurs de kif18a
EP3833350A4 (fr) Inhibiteurs de pyrrolopyrimidine itk
MA52812A (fr) Inhibiteurs de sarm1
EP3802551A4 (fr) Inhibiteurs de protéine de liaison à la pénicilline
IL284664A (en) Multispecific binding proteins
MA52813A (fr) Inhibiteurs de sarm1
EP3817736A4 (fr) Inhibiteurs de pikfyve
MA52809A (fr) Inhibiteurs de sarm1
EP3938358A4 (fr) Inhibiteurs de rad51
EP3661961A4 (fr) Anticorps se liant à l'alpha-synucléine active
DK3737402T5 (da) Modificeret protein
IL284317A (en) Pseudofab-based multispecific binding proteins
EP3765265A4 (fr) Agent liant
MA51611A (fr) Inhibiteurs de pi4kiiibêta
EP3774922A4 (fr) Molécules de liaison impliquant des cellules
IL284570A (en) Quinoline compounds as inhibitors of tam and met kinases